North America to Dominate Neoantigen Cancer Vaccine Market through 2025
Rising prevalence of cancer
and increase in adoption of personalized medicine to drive growth of global
neoantigen cancer vaccine market
According
to TechSci Research report, “Global
Neoantigen
Cancer Vaccine Market By Product (Personalized neo-antigen vaccine, Off-the
shell neoantigen vaccine), By Neoantigen Type (Nucleic Acid, Dendritic Cell,
Tumor Cell, Synthetic long peptide (SLP)), By Route of Administration
(Intravenous, Intramuscular, Transdermal, Others), By Cell (Autologous,
Allogenic), By Technology (Whole Genome Sequencing, Others), By Delivery Mechanism (Gene gun,
Electroporation, Others), By Application (Melanoma, Brain Cancer, Others), By
Region, Competition, Forecast &
Opportunities, 2025”, global neoantigen cancer vaccine market is expected
to register a robust CAGR during the forecast period. Neoantigen cancer
vaccines are the type of vaccines that helps to boost the immune system with
the help of single or few several antigens. Surging prevalence of cancer is one of the
major factor accounting for the growth of global neoantigen cancer
vaccine market. Moreover, rapid adoption of personalized medicines for the patient’s
treatment on the individual level is further expected to bode well for the
growth of global neoantigen cancer vaccine market through the forecast period.
In addition to this, continuous advancements in several drug delivery technologies
is anticipated to positively influence the growth of global neoantigen cancer
vaccine market in the years to come. Also, increased funding for executing
research and development activities is making headway for the growth of global neoantigen
cancer vaccine market across the globe. Along with this, expected launch of
first neoantigen vaccine Tedopi in the market, is estimated to bolster the
market growth through 2025. However, high cost of personalized cancer vaccines
as well as obstacles in clinical development are the major factor that might restrain
the growth of global neoantigen cancer vaccine market through 2025. Additionally,
payer uncertainty and outcome-based pricing are some other factors acting as
major impediments to the market
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on" Global Neoantigen Cancer
Vaccine Market "
https://www.techsciresearch.com/report/neoantigen-cancer-vaccine-market/4566.html
Global
neoantigen cancer vaccine market can be segmented based on product, neoantigen
type, route of administration, cell, technology, delivery mechanism,
application, company and
region. Considering the delivery mechanism, the market is fragmented into gene
gun, electroporation, liposomes, virosomes and others. The gene gun segment is
anticipated to grow at the high rate during the forecast period. Gene gun
technology has been developed as a nonviral method for gene transfer into
various mammalian tissues. The growth of this segment can be attributed to the
fact that it enables direct transfer of the gene in various tissues. In terms
of technology, the market if fragmented to whole genome sequencing, RNA sequencing
and HLA typing. Out of which, whole genome sequencing technology segment is
forecast to register high growth in the next 5 years on account of studying what
genes are misregulated.
Avidea Technologies, Agenus, Roche, Nouscom,
Merck, Pfizer, Advaxis, Medigene, Genocea Biosciences, Gritstone Oncology,
Gilead Sciences, Eli Lilly, Novogene, Moderna, BioNTech, Ziopharm, ISA
Pharmaceutical, Vaccibody, Brightpath Bio, Vaximm are among others are the
leading players operating in global neoantigen cancer vaccine market. The leading players are adopting several growth strategies
to enhance the market scenario of neoantigen cancer vaccine. Some of the competitive
strategies include partnerships, collaborations, business expansions, as well
as mergers and acquisitions, partnership opportunities in order to diverse
their product portfolio and to strengthen their market position.
Download sample report @ https://www.techsciresearch.com/sample-report.aspx?cid=4566
customers can also request for 10% free customization on
this report.
“North America
is forecast to dominate the global neoantigen cancer vaccine market during the
next 5 years on the account of existence of many key market players in this
region. Along with that, more than half of the nonvaccines exist in North
America region, which is further driving the market growth. Asia-Pacific is
anticipated to register high growth during the forecast period which can be
accredited to rising population that has cancer. Furthermore, mounting
investment in research activities and improvement in healthcare technologies is
expected to aid the growth of neoantigen cancer vaccine market in the region until
2025.”, said Mr. Karan Chechi, Research Director with TechSci Research, a
research based global management consulting firm.
“Global Neoantigen Cancer Vaccine Market By Product
(Personalized neo-antigen vaccine, Off-the shell neoantigen vaccine), By Neoantigen
Type (Nucleic Acid, Dendritic Cell, Tumor Cell, Synthetic long peptide (SLP)), By
Route of Administration (Intravenous, Intramuscular, Transdermal, Others), By Cell
(Autologous, Allogenic), By Technology (Whole Genome Sequencing, Others), By Delivery Mechanism (Gene gun,
Electroporation, Others), By Application (Melanoma, Brain Cancer, Others), By
Region, Competition, Forecast &
Opportunities, 2025” has
evaluated the future growth potential of global neoantigen cancer vaccine market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in global neoantigen cancer vaccine market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]